Videos

This animated video visually explores the distinct mechanisms of action (MOAs) of anticholinergics and VMAT-2 inhibitors in managing tardive dyskinesia. It highlights the efficacy and safety differences between the two drug classes, emphasizing how VMAT-2 inhibitors target dopamine dysregulation at the synaptic level, resulting in more targeted and effective symptom relief compared to the broader and less specific effects of anticholinergics.

This video series offers guidance on performing the Abnormal Involuntary Movement Scale (AIMS) exam, a standardized tool for assessing tardive dyskinesia and other movement disorders. The videos include visual representations of the severity levels for each assessment, helping healthcare providers accurately evaluate and document involuntary movements.

This video showcases comparisons of patients with tardive dyskinesia (TD) before and after treatment, highlighting the visible improvements in involuntary movements. Through real-life examples, it demonstrates how treatment can significantly enhance patients' quality of life.

In this instructional video, Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia. Dr. Jain reviews the components of the AIMS and runs through the steps for conducting the exam, illustrated with clips of a patient (portrayed by an actor) to show the various activation techniques.  

As an April 2023 article published in The Journal of Clinical Psychiatry concluded, “Tardive dyskinesia imposes a substantial burden on patients’ physical, psychological, social, and professional lives and impacts management of their underlying condition.”